Caribou’s allogeneic Car meets a six-month bar
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Asco 2023 movers – maintaining the momentum
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
Asco 2023 – Roche sees Morpheus and takes the red pill
The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.
Asco 2023 – Trop2 could validate Merck’s savvy deal with Kelun
In Trop2 Merck & Co might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.